New Treatment for High Blood Pressure in Adults, Focusing on Lung Artery Constriction

Visual Representation for Lung Disease
Visual Representation for Lung Disease

United States: New tab treatment for adults with high blood pressure have been opened by the US Food and Drug Administration on Tuesday. The treatment primarily focused the adults with high BP due to constriction of lung arteries.

The new drug has added another potential blockbuster drug to the pharmaceutical giant’s portfolio, according to reports by Reuters.

The health experts have briefed that the therapy has been branded by Winrevair and has been approved for treating pulmonary arterial hypertension (PAH). It is noteworthy that as many as 40,000 people in the United States have been dealing with the above-mentioned sickness.

After the announcement of the drug, the president of Merck’s US Human Health Business – Jannie Oosthuizen mentioned, “We look forward to making a significant difference for these patients that are left with a disease where the five year mortality is 43 percent,” as quoted by Reuters.

Winrevair will have a list price of USD 14,000 per vial, as stated by Oosthuizen. Based on data gleaned from the company’s trial, the majority of patients will require a solitary vial every three weeks, amounting to USD 238,000 annually.

The pharmaceutical company anticipates being able to introduce the medication to the market by the conclusion of April. Merck obtained the privileges to Winrevair as a component of its USD 11.5 billion procurement of Acceleron Pharma in 2021.

Visual Representation for Lung Disease | Credits: Adobe Stock

It has been fortifying its assortment of cardiovascular medications as part of its strategy to counter a potential blow to revenue from its cancer remedy Keytruda, the preeminent medication globally, from biosimilars in the latter part of the decade.

Winrevair, known chemically as sotatercept, becomes the inaugural treatment to obtain FDA endorsement from its category of medications, which aim at a form of protein termed activin.

PAH stems from a narrowing of arteries in the lungs, resulting in elevated blood pressure and manifestations such as breathlessness, chest discomfort, and vertigo.

Elevated blood pressure also puts greater strain on the heart’s circulation of blood, eventually culminating in heart failure.

In the regard, JP Morgan analyst Chris Schott noted, “We see sotatercept having a strong initial launch and quickly becoming part of the standard of care for eligible PAH patients,” as per Reuters. He further estimated that the sales linked to the drug may peak up to about USD 5 billion by the year 2030.

Merck’s medication gained approval following a 24-week extensive late-stage trial involving 323 PAH patients.

During the trial, individuals administered the medication demonstrated notable enhancement in their exercise capability, with their 6-minute walking distance augmenting by 40.8 meters, in contrast to those who received the placebo.